These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 21671710)

  • 21. Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders.
    Pathak S; Roth M; Verma A; Steidl U
    Expert Opin Drug Metab Toxicol; 2013 Dec; 9(12):1667-75. PubMed ID: 24215532
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Eltrombopag for use in children with immune thrombocytopenia.
    Kim TO; Despotovic J; Lambert MP
    Blood Adv; 2018 Feb; 2(4):454-461. PubMed ID: 29487060
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Moving towards a new era in the management of chronic immune thrombocytopenia.
    Wadenvik H; Olsson B
    Ann Hematol; 2010 Jul; 89 Suppl 1():87-93. PubMed ID: 20339846
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thrombopoietin receptor agonists in the treatment of thrombocytopenia.
    Newland A
    Curr Opin Hematol; 2009 Sep; 16(5):357-64. PubMed ID: 19553811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hemostatic challenges in patients with chronic immune thrombocytopenia treated with eltrombopag.
    Tarantino MD; Bakshi KK; Brainsky A
    Platelets; 2014; 25(1):55-61. PubMed ID: 23402314
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura.
    Kuter DJ
    Eur J Haematol Suppl; 2008 Feb; (69):9-18. PubMed ID: 18211568
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of eltrombopag for secondary immune thrombocytopenia in clinical practice.
    González-López TJ; Alvarez-Román MT; Pascual C; Sánchez-González B; Fernández-Fuentes F; Pérez-Rus G; Hernández-Rivas JA; Bernat S; Bastida JM; Martínez-Badas MP; Martínez-Robles V; Soto I; Olivera P; Bolaños E; Alonso R; Entrena L; Gómez-Nuñez M; Alonso A; Yera Cobo M; Caparrós I; Tenorio M; Arrieta-Cerdán E; Lopez-Ansoar E; García-Frade J; González-Porras JR
    Br J Haematol; 2017 Sep; 178(6):959-970. PubMed ID: 28573819
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful platelet count recovery in lupus-associated thrombocytopenia with the thrombopoietin agonist eltrombopag.
    Scheinberg P; Singulane CC; Barbosa LS; Scheinberg M
    Clin Rheumatol; 2014 Sep; 33(9):1347-9. PubMed ID: 24740463
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune thrombocytopenia -- what are the new treatment options?
    Hallam S; Provan D; Newland AC
    Expert Opin Biol Ther; 2013 Aug; 13(8):1173-85. PubMed ID: 23682685
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
    Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
    J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population PK/PD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy-induced thrombocytopenia.
    Hayes S; Mudd PN; Ouellet D; Johnson BM; Williams D; Gibiansky E
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1507-20. PubMed ID: 23564375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Eltrombopag in thrombocytopenia.
    Lawson A
    N Engl J Med; 2008 Mar; 358(10):1072; author reply 1072-3. PubMed ID: 18322290
    [No Abstract]   [Full Text] [Related]  

  • 33. Eltrombopag in chronic hepatitis C.
    Mihăilă RG; Cipăian RC
    World J Gastroenterol; 2014 Sep; 20(35):12517-21. PubMed ID: 25253952
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of eltrombopag in management of bleeding symptoms associated with chronic immune thrombocytopenia.
    Tarantino MD; Fogarty P; Mayer B; Vasey SY; Brainsky A
    Blood Coagul Fibrinolysis; 2013 Apr; 24(3):284-96. PubMed ID: 23492914
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Eltrombopag therapy in newly diagnosed steroid non-responsive ITP patients.
    Tripathi AK; Shukla A; Mishra S; Yadav YS; Yadav DK
    Int J Hematol; 2014 Apr; 99(4):413-7. PubMed ID: 24526570
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.
    McHutchison JG; Dusheiko G; Shiffman ML; Rodriguez-Torres M; Sigal S; Bourliere M; Berg T; Gordon SC; Campbell FM; Theodore D; Blackman N; Jenkins J; Afdhal NH;
    N Engl J Med; 2007 Nov; 357(22):2227-36. PubMed ID: 18046027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.
    Bussel JB; Cheng G; Saleh MN; Psaila B; Kovaleva L; Meddeb B; Kloczko J; Hassani H; Mayer B; Stone NL; Arning M; Provan D; Jenkins JM
    N Engl J Med; 2007 Nov; 357(22):2237-47. PubMed ID: 18046028
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of eltrombopag, a thrombopoietin receptor agonist, in post-transplantation thrombocytopenia.
    Reid R; Bennett JM; Becker M; Chen Y; Milner L; Phillips GL; Liesveld J
    Am J Hematol; 2012 Jul; 87(7):743-5. PubMed ID: 22573520
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Eltrombopag: a novel oral thrombopoietin receptor agonist.
    Corman SL; Mohammad RA
    Ann Pharmacother; 2010 Jun; 44(6):1072-9. PubMed ID: 20460556
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thrombopoietin: too much or too little.
    Newland A
    Hematology; 2012 Apr; 17 Suppl 1():S166-8. PubMed ID: 22507811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.